Rubicon Research Q4 FY26: Revenue Surges 44%, PAT Jumps 112% YoY
Rubicon Research reported Q4 FY26 revenue of ₹513.9 crore, up 44% YoY, and PAT of ₹76.8 crore, up 112% YoY. Full-year revenue grew 37% to ₹1754 crore. The company acquired an 85% stake in Arinna Lifesciences for ₹200 crore. A dividend of ₹1.5 per share was recommended.
The substantial financial growth, strategic acquisition of Arinna Lifesciences, and positive outlook on future pipeline and capacity expansion are material events that will likely have a significant impact on the company's performance and investor perception.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT, along with a significant number of product approvals and a strategic acquisition. The positive outlook on future growth and R&D productivity further supports the positive sentiment.
Rubicon Research Limited announced its Q4 FY26 financial results, reporting a significant year-on-year revenue growth of 44%, reaching ₹5,139 million (513.9 crore). The company also saw a substantial 112% increase in Profit After Tax (PAT), which stood at ₹768 million (76.8 crore).
For the full fiscal year FY26, revenue grew by 37% to ₹17,540 million (1754 crore), and PAT increased by 84% to ₹2,467 million (246.7 crore). The company's operating EBITDA for the quarter was ₹1,190 million (119 crore), a 64% increase year-on-year, and for the full year, it grew by 52% to ₹4,000 million (400 crore).
During the quarter, Rubicon Research received 12 product approvals in FY26 and has 24 products currently under FDA review. The company announced a recommended dividend of 150%, amounting to ₹1.5 per share.
In a strategic move, Rubicon Research acquired an 85% stake in Arinna Lifesciences for ₹200 crore (enterprise value) to strengthen its presence in the Indian CNS market. The company also expects its Pithampur facility to ramp up within 12-18 months post-FDA inspection, aiming for decent capacity utilization.
The company's R&D spend for Q4 FY26 was 11.6% of operating revenues, with an updated R&D productivity multiple of 5.9x for FY26 over FY23. Rubicon Research has guided an R&D spend of ₹500 crore over nine quarters (FY26, FY27, and Q1 FY28). The board has also approved a proposal to create an ESOP pool, subject to shareholder approval.
What to do with a filing like this
Rubicon Research Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Rubicon Research Limited. Read the original for the full detail.